Duchenne Muscular Dystrophy Trial Case Study

This case study outlines a two-phase clinical trial for Duchenne Muscular Dystrophy (DMD), focusing on patients aged 7 to 13 and young adults. The trial begins with a double-blind administration of an investigational medicinal product (IMP) followed by an open-label phase, allowing patients to continue treatment for up to five years. The study aims to evaluate the impact of a new IMP on DMD symptoms. Recruitment has been facilitated by MRN's Home Trial Support service, which provides home visits for vulnerable patients, ensuring their safety during the COVID-19 pandemic. The study has been ongoing since 2018 and involves multiple countries, with significant patient engagement and protocol adaptations. The case study highlights the challenges and successes of managing a complex clinical trial in a sensitive patient population, particularly during a global health crisis. The collaborative approach has resulted in increased patient enrollment and continuity of care, critical for the trial's success and future drug approval.